Sutent (sunitinib malate)

Company
Pfizer

Approval Status
Approved May 2011

Treatment for
pancreatic neuroendocrine tumors

Possible similar drugs
Sutent

Areas
Diabetes / Endocrinology , Gastrointestinal , Cancer & Oncology

Sutent (sunitinib malate) an oral multi-kinase inhibitor and works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer.

Sutent is specifically indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.

Sutent is supplied as a tablet for oral administration. The recommended dose for pancreatic meuroendocrine tumors is 37.5 mg taken orally once daily continuously without a scheduled off-treatment period.

FDA Approval
The FDA approval of Sutent for pancreatic neuroendocrine tumors was based on a multi-center, international, randomized, double-blind placebo-controlled study in 171 subjects with unresectable pNET. The subjects were randomized to either 37.5 mg Sutent or placebo once daily without a scheduled off-treatment period. The primary endpoint was Progression-Free Survival (PFS). The median PFS in the Sutent arm was 10.2 months versus 5.4 months in the placebo arm. The Objective Response Rate was 9.3% versus 0%, respectively.

Adverse events associated with the use of Sutent for pNET may include, but are not limited to, the following:

  • fatigue
  • asthenia
  • diarrhea
  • nausea
  • stomatitis
  • vomiting
  • abdominal pain
  • hypertension
  • bleeding

Sutent (sunitinib malate) an oral multi-kinase inhibitor and works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer. Two Sutent targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), are expressed by many types of solid tumors and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, oxygen and nutrients needed for growth. Sutent also inhibits other targets important to tumor growth, including KIT, FLT3 and RET.

For additional information regarding Sutent or pancreatic neuroendocrine tumors, please visit the Sutent web page.

Sutent_1147 Drug Information

The Sutent_1147 drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top